Despite encouraging clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant resistance from PBMs. The insurers are often erecting limitations to access, such as steep price restrictions and PA that limit consumer access. Industry indicate that these reimbursement challenge